About NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial (NDUFS3) is a protein
from Homo sapiens identified by UniProt accession
O75489, 264 residues long.
MolForge cross-references it against 0 known binders and
349 disease associations.
Target properties
| Protein name | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial |
|---|
| UniProt accession | O75489 |
|---|
| Gene | NDUFS3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 264 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (349)
Diseases linked to this target (Open Targets).
- mitochondrial complex I deficiency · score 0.69
- type 2 diabetes mellitus · score 0.62
- diabetes mellitus · score 0.60
- polycystic ovary syndrome · score 0.60
- type 1 diabetes mellitus · score 0.58
- gestational diabetes · score 0.58
- Leigh syndrome · score 0.57
- obesity · score 0.57
- prediabetes syndrome · score 0.56
- metabolic syndrome · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75489-F1 | alphafold | PREDICTED | 82.43 | — |
Amino-acid sequence (264 residues)
MAAAAVARLW WRGILGASAL TRGTGRPSVL LLPVRRESAG ADTRPTVRPR NDVAHKQLSA FGEYVAEILP KYVQQVQVSC FNELEVCIHP DGVIPVLTFL RDHTNAQFKS LVDLTAVDVP TRQNRFEIVY NLLSLRFNSR IRVKTYTDEL TPIESAVSVF KAANWYEREI WDMFGVFFAN HPDLRRILTD YGFEGHPFRK DFPLSGYVEL RYDDEVKRVV AEPVELAQEF RKFDLNSPWE AFPVYRQPPE SLKLEAGDKK PDAK
Explore NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets